Milestone payments could take the total value of the deal to over $112 million.

Sanofi pasteur exclusively licensed Crucell’s rabies mAbs. Crucell could earn up to $112.7 million through this agreement.
Crucell will receive $14.73 million, or 10 million, following the execution of the agreement. The company is also eligible to milestone fees of up to $97.97 million, or 66.5 million.

Crucell says it has developed a combination of two compounds that have shown preclinical results comparable to current immunoglobulin products. These biologics will be combined with a vaccine as a post-exposure prophylaxis, according to the firms.

Crucell will continue to develop the candidates and will manufacture the final product.

Previous articleA Glitch in Cells’ Recycling Process Found to Trigger Parkinson’s
Next articleThird Mechanism for Activating Ion Channels Identified